HG-202

N/A

Report date: 2026/04/13 20:02:18

Base Information

Drug NameHG-202
Drug Alias NameHG-202HG202
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vectorCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas13Cell and gene therapy > Gene therapy > Gene editing > RNA editing
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsWet age-related macular degenerationMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHuiGene Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHuidaGene Therapeutics Co LtdHuiGene Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsWet age-related macular degenerationMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A